Overcoming the prokaryote/eukaryote barrier in tuberculosis treatment: A prospect for the repurposing and use of antiparasitic drugs

Ezquerra-Aznárez J.M. (Universidad de Zaragoza) ; Almeida da Silva P.E. ; Aínsa J.A. (Universidad de Zaragoza)

Resumen: Antimicrobial resistance, the so-called silent pandemic, is pushing industry and academia to find novel antimicrobial agents with new mechanisms of action in order to be active against susceptible and drug-resistant microorganisms. In the case of tuberculosis, the need of novel anti-tuberculosis drugs is specially challenging because of the intricate biology of its causative agent, Mycobacterium tuberculosis. The repurposing of medicines has arisen in recent years as a fast, low-cost, and efficient strategy to identify novel biomedical applications for already approved drugs. This review is focused on anti-parasitic drugs that have additionally demonstrated certain levels of anti-tuberculosis activity; along with this, natural products with a dual activity against parasites and against M. tuberculosis are discussed. A few clinical trials have tested antiparasitic drugs in tuberculosis patients, and have revealed effective dose and toxicity issues, which is consistent with the natural differences between tuberculosis and parasitic infections. However, through medicinal chemistry approaches, derivatives of drugs with anti-parasitic activity have become successful drugs for use in tuberculosis therapy. In summary, even when the repurposing of anti-parasitic drugs for tuberculosis treatment does not seem to be an easy job, it deserves attention as a potential contributor to fuel the anti-tuberculosis drug pipeline.

Idioma: Inglés

DOI: 10.3390/microorganisms9112335

Año: 2021

Publicado en: Microorganisms 9, 11 (2021), 2335 [16 pp.]
ISSN: 2076-2607

Factor impacto JCR: 4.926 (2021)

Categ. JCR: MICROBIOLOGY rank: 54 / 137 = 0.394 (2021) - Q2 - T2

Factor impacto CITESCORE: 4.1 - Medicine (Q2) - Immunology and Microbiology (Q3)

Factor impacto SCIMAGO: 0.862 - Microbiology (medical) (Q2) - Microbiology (Q2)

Financiación: info:eu-repo/grantAgreement/ES/MCIU/FPU18-03873

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)